Literature DB >> 16183333

Protease-activated receptor-2 (PAR2) in cardiovascular system.

Mariarosaria Bucci1, Fiorentina Roviezzo, Giuseppe Cirino.   

Abstract

Vascular system is constituted by a complex and articulate network, e.g. arteries, arterioles, venules and veins, that requires a high degree of coordination between different elemental cell types. Proteinase-activated receptors (PARs) constitute a recent described family of 7-transmembrane G protein-coupled receptors that are activated by proteolysis. In recent years several evidence have been accumulated for an involvement of this receptor in the response to endothelial injury in vitro and in vivo experimental settings suggesting a role for PAR2 in the pathophysiology of cardiovascular system. This review will deal with the role of PAR2 receptor in the cardiovascular system analyzing both in vivo and in vitro published data. In particular this review will deal with the role of this receptor in vascular reactivity, ischemia/reperfusion injury, coronary atherosclerotic lesions and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183333     DOI: 10.1016/j.vph.2005.07.009

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  7 in total

1.  Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method.

Authors:  Aaron M Miller; Nephi Stella
Journal:  Glia       Date:  2009-06       Impact factor: 7.452

2.  Renal proteinase-activated receptor 2, a new actor in the control of blood pressure and plasma potassium level.

Authors:  Luciana Morla; Gaëlle Brideau; Marc Fila; Gilles Crambert; Lydie Cheval; Pascal Houillier; Sureshkrishna Ramakrishnan; Martine Imbert-Teboul; Alain Doucet
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

3.  Cross-talk between toll-like receptor 4 (TLR4) and proteinase-activated receptor 2 (PAR(2) ) is involved in vascular function.

Authors:  M Bucci; V Vellecco; L Harrington; V Brancaleone; F Roviezzo; G Mattace Raso; A Ianaro; G Lungarella; R De Palma; R Meli; G Cirino
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Lipopolysaccharide pretreatment increases protease-activated receptor-2 expression and monocyte chemoattractant protein-1 secretion in vascular endothelial cells.

Authors:  Hung-Hsing Chao; Po-Yuan Chen; Wen-Rui Hao; Wei-Ping Chiang; Tzu-Hurng Cheng; Shih-Hurng Loh; Yuk-Man Leung; Ju-Chi Liu; Jin-Jer Chen; Li-Chin Sung
Journal:  J Biomed Sci       Date:  2017-11-15       Impact factor: 8.410

5.  Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.

Authors:  Amanda J Kennedy; Linda Sundström; Stefan Geschwindner; Eunice K Y Poon; Yuhong Jiang; Rongfeng Chen; Rob Cooke; Shawn Johnstone; Andrew Madin; Junxian Lim; Qingqi Liu; Rink-Jan Lohman; Anneli Nordqvist; Maria Fridén-Saxin; Wenzhen Yang; Dean G Brown; David P Fairlie; Niek Dekker
Journal:  Commun Biol       Date:  2020-12-17

Review 6.  Proteases and Their Potential Role as Biomarkers and Drug Targets in Dry Eye Disease and Ocular Surface Dysfunction.

Authors:  Alba Ramos-Llorca; Camilla Scarpellini; Koen Augustyns
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

7.  PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion.

Authors:  Kristoffer B Hansen; Christian Staehr; Palle D Rohde; Casper Homilius; Sukhan Kim; Mette Nyegaard; Vladimir V Matchkov; Ebbe Boedtkjer
Journal:  Elife       Date:  2020-09-21       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.